The anti-tumor efficacy of engineered bacteria alone or combined with anti-Programmed cell death 1 ligand 1 (aPD-L1) immunotherapy were evaluated on subcutaneous tumor models and orthotopic glioblastoma models. Here, CD274 is linked to neoplasm.